Oppenheimer has upgraded Agios Pharmaceuticals Inc AGIO shares to Outperform from Perform on higher expectations for its first drug launch and attractive valuation.
The company’s AG-221, developed along with partner Celgene Corporation CELG, is submitted for FDA approval for mutant isocitrate dehydrogenase-2 (IDH2) in advanced hematologic malignancies. The brokerage estimates that AG-221 could launch in the fourth quarter of 2017.
In addition, AG-120 is being studied in isocitrate dehydrogenase-1 (IDH1) mutant positive glioma and chondrosarcoma.
“We anticipate Agios will launch its first drug, AG-221, in partnership with Celgene Corporation, in 2017 and its second drug, AG-120, in 2018, two years sooner than we previously estimated,” analyst Leah Rush Cann wrote in a note.
Analyst's Estimations
The analyst estimates Agios’ total revenue will grow at a CAGR of 70.9 percent for the next six years, increasing to $1.47 billion in 2021.
Rush Cann also projects AG-221 could result in 2021 product sales of $1.4 billion and 2021 royalty income to Agios of nearly $172 million.
Further, the analyst anticipates AG-120 could result in 2021 product sales to Agios of $1.278 billion, significantly higher than prior estimate of $55 million.
At last check, shares of Agios were down 0.96 at $41.15. The analyst has a price target of $75.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.